Theravance Biopharma (NASDAQ:TBPH) Reaches New 1-Year High – Here’s What Happened

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) hit a new 52-week high during trading on Tuesday . The company traded as high as $21.00 and last traded at $20.30, with a volume of 108589 shares. The stock had previously closed at $20.01.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on TBPH shares. BTIG Research increased their price objective on shares of Theravance Biopharma from $25.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, November 26th. Oppenheimer assumed coverage on shares of Theravance Biopharma in a research note on Wednesday, December 3rd. They set an “outperform” rating and a $27.00 target price for the company. Weiss Ratings reissued a “hold (c)” rating on shares of Theravance Biopharma in a report on Wednesday, October 8th. Wall Street Zen lowered Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. Finally, HC Wainwright upped their price objective on Theravance Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $27.80.

Theravance Biopharma Stock Performance

The business’s 50-day moving average price is $18.70 and its 200-day moving average price is $15.16. The stock has a market cap of $1.03 billion, a P/E ratio of 35.82 and a beta of 0.14.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Monday, November 10th. The biopharmaceutical company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.10. Theravance Biopharma had a return on equity of 12.20% and a net margin of 36.53%.The company had revenue of $19.99 million for the quarter, compared to analysts’ expectations of $19.89 million. As a group, equities research analysts expect that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.

Insider Activity

In related news, SVP Rhonda Farnum sold 31,067 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $18.75, for a total value of $582,506.25. Following the completion of the sale, the senior vice president directly owned 277,695 shares of the company’s stock, valued at approximately $5,206,781.25. This represents a 10.06% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in TBPH. Quarry LP purchased a new stake in Theravance Biopharma during the 3rd quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Theravance Biopharma by 107.4% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 1,411 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Theravance Biopharma by 18.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 781 shares during the last quarter. CIBC Private Wealth Group LLC grew its stake in Theravance Biopharma by 20,269.6% during the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after acquiring an additional 4,662 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in Theravance Biopharma in the 3rd quarter valued at $101,000. Institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.